Amneal Pharmaceuticals
AMRX

$7.44

0.81%

Market Cap: 2.3B

About: Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Employees: 7,700

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 5 analysts

0

News positive %

of 6 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

800% more call options, than puts

Call options by funds: $4.53M | Put options by funds: $503K

263% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 8

100% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 2 (+1) [Q1 2024]

38% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 48

14% more funds holding

Funds holding: 152 [Q4 2023] → 173 (+21) [Q1 2024]

4% less capital invested

Capital invested by funds: $677M [Q4 2023] → $651M (-$26.4M) [Q1 2024]

1.35% less ownership

Funds ownership: 36.4% [Q4 2023] → 35.05% (-1.35%) [Q1 2024]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$6.25

16%

downside

Avg. target

$7.85

6%

upside

High target

$9

21%

upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

Goldman Sachs Nathan Rich	8%upside $8	Buy Maintained	6 May 2024
Truist Securities Les Sulewski	21%upside $9	Buy Reiterated	6 May 2024
Piper Sandler David Amsellem	8%upside $8	Overweight Maintained	21 Mar 2024
Goldman Sachs Nathan Rich	16%downside $6.25	Buy Maintained	4 Mar 2024
Barclays Balaji Prasad	8%upside $8	Overweight Maintained	29 Jan 2024

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about AMRX published over the past 30 days

Amneal to Report Second Quarter 2024 Results on August 9, 2024

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. Individuals m.

Amneal to Report Second Quarter 2024 Results on August 9, 2024

Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success

Amneal Pharmaceuticals has seen a significant increase in its share price of >400% after hitting an all-time low in March 2023. The company reported record revenues in Q1 2024, with growth in all three reportable segments - Generics, Specialty, and AvKare. Amneal is projecting new product launches and international expansion to add multi-billions of dollars of revenues by 2027, and profitability - on an adjusted basis at least - is in evidence.

Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success

Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced the launch of FOCINVEZ™, a ready-to-use injectable. Unlike other versions of fosaprepitant, this single-dose vial product is free of Polysorbate 80 and does not require reconstitution or dilution and can be administered directly from the vial using the included vial hanger. FOCINVEZ for injection is indicated in adults and pediatric patients 6 months of age and older, in c.

Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant

Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that it has entered into an exclusive licensing agreement for ADL018, a proposed biosimilar to omalizumab referencing XOLAIR®, with Amneal Pharmaceuticals, Inc. (“Amneal”) for the United States. Omalizumab, which targets free IgE, is a humanized monoclonal antibody. It is an injectable prescription drug used to treat a number of chronic conditions such as severe persistent allergic asthma, chr.

Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)

Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the addition of omalizumab, referencing XOLAIR®, to its biosimilar pipeline. Omalizumab is a humanized monoclonal antibody which targets free immunoglobulin E (IgE). It is an injectable prescription drug used to treat a number of chronic conditions such as severe persistent allergic asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), food allergies, and chronic spon.

Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar

Amneal Releases 2023 Environmental, Social and Governance Report

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the release of its fourth (2023) Environmental, Social and Governance (ESG) Report. This 2023 report provides a look at our progress against our core ESG priorities, including our commitment to embedding sustainability across our business; human capital management, including well-being, inclusion and belonging efforts; philanthropic partnerships with health-related non-pro.

Amneal Releases 2023 Environmental, Social and Governance Report

Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the continued expansion of its injectables portfolio with six new injectable product launches during the second quarter of 2024, bringing the Company's total number of commercial injectable products available for the U.S. institutional market to over 40. The growth of Amneal's broad injectables portfolio will help address shortages of critical products where there may be l.

Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies

Amneal to Participate at Upcoming Investor Conference

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Participate at Upcoming Investor Conference.

Amneal to Participate at Upcoming Investor Conference

Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California.

Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California

Amneal Pharmaceuticals, Inc. (AMRX) Q1 2024 Earnings Call Transcript

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q1 2024 Results Earnings Conference Call May 3, 2024 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President and Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Tasos Konidaris - Executive Vice President and Chief Financial Officer Joe Renda - Senior Vice President, Chief Commercial Officer, Specialty Conference Call Participants Nathan Rich - Goldman Sachs Leszek Sulewski - Truist Securities David Amsellem - Piper Sandler Balaji Prasad - Barclays Capital Chris Schott - J.P. Morgan Operator Good morning and welcome to Amneal Pharmaceuticals First Quarter 2024 Earnings Call.

Amneal Pharmaceuticals, Inc. (AMRX) Q1 2024 Earnings Call Transcript

See News Rankings